News
NICE turns down Celgene’s Revlimid as multiple myeloma maintenance treatment
The National Institute for Heath and Care Excellence (NICE) has turned down NHS funding of Celgene’s Revlimid (lenalidomide) as maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.